Evidence map›Paper›PMID 38891089›Full record

ArticleCells2024

Stable Dietary Ora-Curcumin Formulation Protects from Experimental Colitis and Colorectal Cancer.

Chaitanya K Valiveti, Balawant Kumar, Anuj D Singh, Sham K Biradar, Rizwan Ahmad, Amar B Singh, Hemachand Tummala

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chaitanya K ValivetiDepartment of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, South Dakota State University, Brookings, SD 57007, USA.
Balawant KumarDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0002-8187-3078
Anuj D SinghDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Sham K BiradarDepartment of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, South Dakota State University, Brookings, SD 57007, USA.
Rizwan AhmadDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.ORCID 0000-0003-0331-6687
Amar B SinghDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Hemachand TummalaDepartment of Pharmaceutical Sciences, College of Pharmacy & Allied Health Professions, South Dakota State University, Brookings, SD 57007, USA.

Funding

Strategy for Safe Colon-targeted Local Therapy of Inflammatory Bowel DiseaseR15DK125940 · NIDDK · SOUTH DAKOTA STATE UNIVERSITY · PI TUMMALA, HEMACHAND · 2021 to 2021
$441k
NIDDK NIH HHS R15 DK125940NIH HHS 1R15DK125940NIH HHS DK124095VA-merit award BX002761
6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic gut disorder that also elevates the risk of colorectal cancer (CRC). The global incidence and severity of IBD are rising, yet existing therapies often lead to severe side effects. Curcumin offers potent anti-inflammatory and chemotherapeutic properties. However, its clinical translation is hindered by rapid metabolism, as well as poor water solubility and stability, which limits its bioavailability. To address these challenges, we developed OC-S, a water-soluble and colon-targeted curcumin formulation that protects against colitis in mice. The current study advances OC-S as a dietary supplement by establishing its stability and compatibility with various commercial dietary products. Further, OC-S exhibited specific binding to inflamed colon tissue, potentially aiding in targeted drug retention at the inflammation site in colitis with diarrhea symptoms. We further investigated its efficacy in vivo and in vitro using a murine model of colitis and tumoroids from APC

Indexed as

ColitisColorectal NeoplasmsCurcuminAnimalsCell ProliferationDietary SupplementsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLProtective AgentsCurcuminProtective AgentsCRCcurcumindietary productsIBDOra-curcuminpolymer–drug complexes

Identifiers

PMID38891089
PMCPMC11172195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.